Tesamorelin: A Research Overview for Australian Researchers

Tesamorelin is one of the few growth-hormone-releasing analogues to have completed full Phase 3 trials and received FDA approval — specifically for HIV-associated lipodystrophy. For Australian researchers, that regulatory pedigree makes it one of the better-characterised GHRH analogues in the published literature.

What tesamorelin is

Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH). The native GHRH research compound has a very short plasma half-life because it's rapidly cleaved by dipeptidyl peptidase. Tesamorelin has a trans-3-hexenoic acid modification on the N-terminus that resists this cleavage, extending its biological half-life.

Mechanism

Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth-hormone secretion in a pulsatile pattern. The downstream effect on circulating IGF-1 is dose-dependent. Because secretion remains pulsatile (rather than constant), the negative-feedback loop on the hypothalamic axis stays largely intact — a profile distinct from exogenous growth-hormone administration.

Published clinical data

The two pivotal Phase 3 trials (Falutz et al., NEJM 2007 and 2008) examined tesamorelin in HIV patients with excess visceral adipose tissue. Across both trials:

• Visceral adipose tissue reduction of ~15–18% at 26 weeks vs ~5% on placebo.
• IGF-1 levels increased into the normal-high physiological range, without crossing into supraphysiological territory in the majority of participants.
• Subcutaneous fat was largely preserved — the effect was selective to visceral depots.

Half-life and administration

Plasma half-life is ~26–38 minutes; biological effect (measured by GH release) is longer. Trial protocols used 2 mg subcutaneous injection daily, typically at bedtime to align with natural GH pulses.

Comparison with other GHRH analogues

• vs CJC-1295 (no DAC): similar GHRH activity, slightly shorter half-life on CJC-1295. Tesamorelin has substantially more human clinical data.
• vs CJC-1295 + DAC: DAC variant extends half-life to days rather than minutes, producing tonic rather than pulsatile GH elevation. A materially different pharmacologic profile.
• vs Sermorelin: sermorelin is the original GHRH (1-29) fragment without tesamorelin's stabilising modification — shorter duration of action, less robust IGF-1 response in published comparisons.

Storage

Tesamorelin is one of the more fragile research compounds. Reconstituted vials should be refrigerated and ideally used within 7–14 days. See our storage guide for best practice.

Sourcing

Research-grade material is available via tesamorelin 10mg, shipped from within Australia. For the full mechanism deep-dive, see the tesamorelin research guide.